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Infection Influence the Choice of Empiric Antibiotics for 
Community-acquired Pneumonia in a Tuberculosis-endemic Area?
Yuan-Yu Jenga, Yi-Tsung Lina, Ling-Ju Huanga,b, Te-Li Chena,b*, Fu-Der Wanga,b, Chang-Phone Funga,b, 
Cheng-Yi Liua,b
aDivision of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
bSchool of Medicine, National Yang-Ming University, Taipei, Taiwan.
BACKGROUND/PURPOSE: Recent medical literature suggests that use of fluoroquinolones (FQs) 
might be associated with the delayed diagnosis of pulmonary tuberculosis (TB). The purpose of this study 
was to assess the impact of radiographic evidence of prior pulmonary TB infection on empiric antibiotic 
choice in cases of community-acquired pneumonia (CAP), as well as the effect of antibiotic regimens on 
clinical outcome.
METHODS: A total of 280 patients with CAP between 1 May and 31 December 2007 were included in the 
study and their medical records were retrospectively reviewed. Patients were divided into two groups: 
those receiving FQs (FQ group) or those receiving β-lactam-based regimens (β-lactam group). Their 
demographic data, underlying diseases, clinical features, diseases severity and outcomes were compared. 
RESULTS: Radiographic evidence of a previous pulmonary TB infection (odds ratio = 3.507, 95% confi-
dence interval = 1.422–8.645; p =  0.006) was an independent factor associated with β-lactam-based regi-
mens. Patients with a modified pneumonia severity index (mPSI) category V were more likely to receive 
FQ therapy (odds ratio = 2.53, 95% confidence interval = 1.140–5.615; p =  0.022). Of the patients with 
mPSI category V, the 14-day mortality rate of those in the β-lactam group was significantly lower than 
that of those in the FQ group (0% vs. 23%, respectively; p =  0.044).
CONCLUSION: Radiographic evidence of a previous pulmonary TB infection and a lower mPSI score 
increases the probability of the selection of a β-lactam-based regimen for the treatment of CAP.
KEYWORDS: β-lactam, community-acquired pneumonia, fluoroquinolone, tuberculosis
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Introduction
Community-acquired pneumonia (CAP) is a common in-
fection associated with considerable morbidity, mortality 
and costs.1–4 In contrast to other antibiotics used to treat 
CAP, fluoroquinolones (FQs) have excellent in vitro activ-
ity against Mycobacterium tuberculosis.5,6 The empirical use 
of FQs in pulmonary tuberculosis (TB) patients who ini-
tially present with a clinical picture of CAP is associated 
with temporary improvement in pulmonary and systemic 
symptoms and signs.7,8 However, these effects might also 
lead to delayed diagnosis of TB and prolonged infectivity, 
greater morbidity and mortality, and a prolonged period 
of spread of M. tuberculosis in the community.7,8 In Taiwan, 
the annual incidence of TB has remained high, ranging 
from 62.7 per 100,000 population in 2000 to 63.2 per 
100,000 population in 2007.9 In a recent surveillance 
study in eight Asian countries, TB accounted for 3.0% 
(13/428) of CAP among those with a known microbio-
logical etiology.10 The issue of whether FQs should be the 
first-line antibiotics to treat CAP in TB-endemic areas is 
still controversial.11,12 In an era of increasing awareness of 
TB infection and the announcement of judicious use of 
FQs, we conducted a study to evaluate whether any hint 
of a prior TB infection will influence the choice of empiric 
antibiotics for CAP treatment, and to compare the clinical 
outcomes of patients receiving different regimens.
Methods
Study design
The study was conducted at Taipei Veterans General 
Hospital, a 2,900-bed tertiary teaching medical center. 
This was a retrospective cohort study and included all 
patients hospitalized with a diagnosis of CAP between 
May 1 and December 31, 2007.
Inclusion criteria
Patients aged ≥ 18 years were eligible for the study if they 
had a diagnosis of pneumonia acquired in the commu-
nity and had been admitted to hospital. These patients 
satisfied the definition of CAP suggested by the Infectious 
Disease Society of America:13 (1) they had an acute illness 
(symptom onset within 10 days); (2) they had a new chest 
radiographic infiltrate confirmed by a radiologist; and 
(3) they had clinical signs suggestive of acute pneumonia, 
including either one major criterion [fever (aural tempera-
ture > 38°C), hypothermia (aural temperature < 35°C), 
cough or sputum production] or two minor criteria (dys-
pnea, pleuritic pain, clinical evidence of lung consolida-
tion, or a leukocyte count > 10,000/μL or < 4,500/μL). For 
this study, patients must have received either a β-lactam-
based regimen or “respiratory” FQs (moxifloxacin or levo-
floxacin) within the first 24 hours after presentation at 
the hospital and must have remained on therapy for at 
least 48 hours after admission.
Exclusion criteria
Patients were excluded if they: (1) died within the first 24 
hours after presentation at the hospital; (2) had been resi-
dent in a long-term care facility for ≥ 14 days; (3) were hos-
pitalized during the 90 days prior to admission; (4) had a 
human immunodeficiency virus (HIV) infection; (5) had 
primary or metastatic malignancy in the lung paren-
chyma; (6) had an absolute neutrophil count ≤ 1,000/μL; 
or (7) were receiving β-lactam plus FQs concomitantly.
Patient data
A structured data instrument collected the following data 
from the patients’ medical records: demographic factors, 
medical history and comorbid diseases, physical examina-
tion, laboratory, image findings and antibiotic treatment. 
The presence of the following comorbid conditions was 
documented: diabetes mellitus, HIV infection, neoplastic 
disease, liver disease, heart failure, cerebrovascular and 
renal disease. The modified pneumonia severity index 
(mPSI)14 scores were calculated based on the worst physi-
ological score derived from physical and laboratory find-
ings collected in our hospital within the first 24 hours. 
We did not include arterial pH < 7.35 in our mPSI calcula-
tion as blood gas analysis was not performed on all pa-
tients. Radiographic evidence of prior pulmonary TB 
infection was defined as fibronodular lesions, fibrocalci-
fied lesions, or apical pleural thickening that was reported 
by radiologists.
Microbiology
To identify M. tuberculosis complex, specimens were cul-
tured on Lowenstein-Jensen and Middlebrook 7H11 me-
dium. Mycobacteria were identified using phenotypic 
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tests.15 For bacterial pathogens other than mycobacteria, 
specimens collected within the first 48 hours of admis-
sion were cultured and identified using standard micro-
biological techniques.16 Legionella was identified using the 
urinary antigen assay (Binax Inc., Portland, Maine, USA). 
A definite etiology was established by the recovery of a 
probable etiologic agent from an uncontaminated speci-
men (blood). A probable etiologic diagnosis was estab-
lished by culture of a likely pulmonary pathogen in 
respiratory secretions (expectorated sputum or aspirate 
from an endotracheal tube).
Outcomes
The following clinical outcomes were noted: (1) respira-
tory failure with requirement for mechanical ventilation; 
(2) length of hospital stay ; (3) all available mycobacterial 
examinations within 180 days of hospital admission; (4) 
vital status 30 days after hospital admission (30-day mor-
tality); and (5) vital status during hospital admission (in-
hospital mortality). Outcomes were compared between 
treatment groups for the entire population and also 
between each mPSI class.
Data analysis
Qualitative variables were compared using the χ2 or 
Fisher’s exact tests, and quantitative variables were com-
pared using Student’s t test. Multivariate analyses were 
performed to determine the independent factors affecting 
the choice of antibiotic regimen. For all analyses, a p 
value < 0.05 was considered significant for two-tailed 
tests. The 30-day survival probability was derived using 
the Kaplan-Meier method. SPSS version 15.0 was used for 
all calculations (SPSS Inc., Chicago, IL, USA).
Results
A total of 551 patients were hospitalized with a diagno-
sis of pneumonia during the study period. However, 
271 patients were excluded, including those who died 
within the first 24 hours after presentation at the hospital 
(3 patients), who had been resident in a long-term care 
facility (183 patients), who had been hospitalized in 
another hospital due to the same CAP episode (29 pa-
tients), who had had primary or metastatic malignancy in 
the lung parenchyma (53 patients), and those receiving 
concomitant β-lactam plus FQ therapy (3 patients). Of 
the 280 CAP patients who met the inclusion criteria, 227 
received β-lactam-based therapy, and 53 received FQ mon-
otherapy for at least 48 hours after admission (Table 1). A 
comparison of baseline clinical and laboratory character-
istics between treatment groups is shown in Table 2. 
Univariate analysis showed that male gender and patients 
with a history of or radiographic evidence of a prior TB 
infection tended to receive β-lactam-based therapy. 
Patients with malignancy and more severe diseases tended 
to receive FQ-based regimens. Of the patients who had ra-
diographic evidence of prior pulmonary TB (n = 80), most 
Table 1. Empiric antibiotic regimens provided to patientsa
Antibiotic regimens n (%)
β-lactam-based therapy (n = 227)
 β-lactam alone 159 (70.04)
  β-lactam/β-lactamase inhibitor 123 (54.19)
  Cephamycins 8 (3.52)
  Second generation cephalosporins 14 (6.17)
  Third generation cephalosporins 10 (4.41)
  Fourth generation cephalosporins 1 (0.44)
  Carbapenem 3 (1.32)
 β-lactam + aminoglycoside 12 (5.29)
   β-lactam/β-lactamase inhibitor + 11 (4.85)
 aminoglycoside
   Second generation cephalosporins + 1 (0.44)
 aminoglycoside
 β-lactam + macrolide 52 (22.91)
   β-lactam/β-lactamase inhibitor + 43 (18.94)
 macrolide
  Cephamycins + macrolide 2 (0.88)
   Second generation cephalosporins + 4 (1.76)
 macrolide
   Third generation cephalosporins + 1 (0.44)
 macrolide 
   Fourth generation cephalosporins + 1 (0.44)
 macrolide
  Carbapenem + macrolide 1 (0.44)
 β-lactam + macrolide + aminoglycoside 2 (0.88)
 β-lactam + minocycline 2 (0.88)
Fluoroquinolones-based therapy (n = 53)
 Moxifloxacin 37 (69.81)
 Levofloxacin 16 (30.19)
aData presented as n (%) of patients with each treatment group. 
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Table 2. Comparison of clinical characteristics between patients receiving empiric β-lactam-based versus fluoroquinolones 
therapya
 All patients  mPSI category V 
Characteristics
 β-lactam (n = 227) FQ (n = 53) p β-lactam (n = 22) FQ (n = 13) p
Age (yr) 76.86 ± 13.36 73.68 ± 15.24 0.166 83.5 ± 7.42 83.0 ± 3.14 0.820
Sex, male 195 (85.9) 39 (73.6) 0.029 21 (95.5) 9 (69.2) 0.052
Underlying diseases
 Neoplastic diseases 21 (9.3) 10 (18.9) 0.045 5 (22.7) 6 (46.2) 0.258
 Liver disease 5 (2.2) 0 (0) 0.276 1 (4.5) 0 (0) 1.000
 Cerebrovascular disease 32 (14.1) 7 (13.2) 0.866 4 (18.2) 4 (30.8) 0.433
 Congestive heart failure 26 (11.5) 5 (9.4) 0.673 5 (22.7) 3 (23.1) 1.000
 Renal disease 26 (11.5) 8 (15.1) 0.465 8 (36.4) 4 (30.8) 1.000
 History of prior TB 33 (14.5) 2 (3.8) 0.033 4 (18.2) 1 (7.7) 0.630
Physical findings
 Alerted mental status 8 (35) 4 (7.5) 0.250 6 (27.3) 3 (23.1) 1.000
 Respiratory rate ≥ 30/min 22 (9.7) 5 (9.4) 0.954 7 (31.8) 5 (38.5) 0.726
  Systolic blood pressure  4 (1.8) 7 (13.2) 0.001 2 (9.1) 3 (23.1) 0.253
 < 90 mmHg
  Body temperature 3 (1.3) 0 (0) 1.000 0 (0) 0 (0) –
  < 35°C or > 40°C
 Pulse rate ≥ 125 beats/min 16 (7.0) 2 (3.8) 0.540 3 (13.6) 1 (7.7) 1
Laboratory findings
 pH < 7.35 11 (4.8) 5 (9.4) 0.196 1 (4.5) 2 (15.4) 0.541
 BUN > 30 mg/dL 22 (9.7) 5 (9.4) 0.954 16 (72.7) 9 (69.2) 1.000
 Sodium < 130 mmol/L 22 (9.7) 3 (5.7) 0.435 9 (40.9) 0 (0) 0.013
 Glucose > 250 mg/dL 19 (8.4) 10 (18.9) 0.024 9 (40.9) 5 (38.5) 0.886
 Hematocrit < 30% 23 (10.1) 13 (24.5) 0.005 8 (36.4) 6 (46.2) 0.568
  PO2 < 60 mmHg or oxygen 25 (11.0) 8 (15.1) 0.407 6 (27.3) 6 (46.2) 0.292
 saturation < 90%
 Albumin (g/dL) 3.06 ± 0.52 2.98 ± 0.59 0.447 2.59 ± 0.54 2.88 ± 0.64 0.227
 CRP (mg/dL) 11.53 ± 8.09 12.04 ± 8.98 0.704 16.6 ± 9.73 15.09 ± 10.6 0.677
Radiographic findings
 Evidence of prior TB 73 (32.2) 7 (13.2) 0.006 6 (27.3) 2 (15.4) 0.680
 Upper lung infiltrate      
  Single lobe 13 (5.7) 1 (1.9) 0.481 0 (0) 0 (0) –
  Multi-lobes 53 (23.3) 16 (30.2) 0.298 9 (40.9) 6 (46.2) 0.762
 Pleural effusion 43 (19.7) 8 (15.4) 0.472 7 (31.8) 2 (16.7) 0.339
 mPSI scoreb 101.53 ± 23.90 107.71 ± 30.42 0.125 149.86 ± 14.86 148.38 ± 15.11 0.776
 mPSI class
  I 11 (4.8) 5 (9.4)
  II 15 (6.6) 4 (7.5)
  III 68 (30.0) 9 (17.0)
  IV 111 (48.9) 22 (41.5)
  V 22 (9.7) 13 (24.5) 0.003
aData presented as n (%) or mean ± standard deviation; bnot include blood gas data. β-lactam = β-lactam-based therapy group; FQ = fluoro-
quinolones therapy group; TB = tuberculosis; BUN = blood urea nitrogen; CRP = C-reactive protein; mPSI = modified pneumonia severity index.
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Table 3. Comparison of causative pathogens for patients receiving empiric β-lactam-based versus fluoroquinolones therapya
Causative pathogen β-lactam (n = 227) FQ (n = 53) p
Streptococcus pneumoniae 4 (1.76) 0 (0) 1.000
Haemophilus influenzae 1 (0.44) 0 (0) 1.000
Klebsiella pneumoniae 20 (8.81) 4 (7.55) 1.000
Staphylococcus aureus 7 (3.08) 4 (7.50) 0.229
Escherichia coli 3 (1.32) 1 (1.89) 0.570
Pseudomonas aeruginosa 10 (4.41) 0 0.217
Citrobacter diversus 0 (0) 1 (1.89) 0.189
Serratia sp. 1 (0.44) 0 (0) 1.000
Unidentified GNF-GNB 1 (0.44) 1 (1.89) 0.343
Mix pathogens 9 (3.96) 1 (1.89) 0.405
Mycobacterium tuberculosis 9 (3.96) 0 (0) 0.216
Total culture positive 65 (28.60) 12 (22.60) 0.494
aData presented as n (%). β-lactam = β-lactam-based therapy group; FQ = fluoroquinolones therapy group; GNF-GNB = glucose non-fermenting 
Gram-negative bacilli.
of them received β-lactam-based therapy (90.1% vs. 9.9%). 
Other radiographic presentations including interstitial 
infiltration, alveolar infiltrate, and lobar infiltration of 
single or multi-upper lobes were not significantly differ-
ent between treatment groups. There were also no signifi-
cant differences in extra-pulmonary symptoms (including 
headache, dizziness, sore throat, myalgia, nausea, vomit-
ing and diarrhea) between the two groups. Multivariate 
analysis showed that the proportion of patients with 
mPSI category V was significantly higher in the FQ group 
than in the β-lactam group (odds ratio = 2.53, 95% confi-
dence interval = 1.140–5.615; p = 0.022), but the propor-
tion of patients with radiographic evidence of prior 
pulmonary TB infection was significantly higher in the β-
lactam group (odds ratio = 3.507, 95% confidence inter-
val = 1.422–8.645; p = 0.006). Other characteristics including 
gender, neoplastic diseases, prior history of TB, anemia 
and hyperglycemia were not significantly different between 
the two treatment groups.
The etiologies of CAP are listed in Table 3. All except 
one were probable diagnoses. Only one definite etiology 
was documented (mixed Escherichia coli and Edwardsiella 
tarda bacteremia). There was no significant difference be-
tween the two treatment groups regarding the causative 
CAP pathogen. Nine patients were diagnosed with pul-
monary M. tuberculosis infection, and they were all in 
β-lactam group. The mean interval between initial hospi-
talization and TB diagnosis was 44.3 days. The Legionella 
urinary antigen assay was performed in 24/280 patients, 
and the results were all negative.
Taking all patients into consideration, there was no 
difference in outcome between the two treatment groups 
(Table 4). The overall in-hospital mortality rate was 7.5% 
(21/280) and the in-hospital mortality rate in each mPSI 
group was 0% (category I, II and III), 7.5% (10/133, cate-
gory IV), and 31.4% (11/35, category V). Comparisons of 
baseline clinical and laboratory characteristics between 
the treatment group with the most severe patient group 
(mPSI category V) are also shown in Table 2. The groups 
differed significantly only in the proportion of patients 
with hyponatremia (Sodium < 130 mmol/L). A higher 
proportion of patients with hyponatremia received β-
lactam-based therapy. However, no significant differences 
in length of hospital stay , 14-day mortality or in-hospital 
mortality were noted between mPSI category V patients 
either with or without hyponatremia (p > 0.23). For pa-
tients with “severe CAP” (mPSI IV + V), there was no sig-
nificant difference in clinical outcome, including 14-day 
mortality, in-hospital mortality, length of hospital stay 
and the use of mechanical ventilation between the two 
treatment groups. Of the patients with mPSI category V, 
the 14-day mortality rate was significantly lower for those 
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Table 4. Comparison of outcomes of patients receiving empiric β-lactam-based versus fluoroquinolones therapya
 β-lactam FQ p
14-day mortality 
 All patients 4/227 (1.8) 3/53 (5.7) 0.128
 mPSI IV 4/111 (3.6) 0/22 (0) 1.000
 mPSI V 0/22 (0) 3/13 (23.1) 0.044
 mPSI IV + V 4/133 (3.0) 3/35 (8.6) 0.159
In-hospital mortality
 All patients 15/227 (6.6) 6/53 (11.3) 0.250
 mPSI IV 9/111 (8.1) 1/22 (4.5) 1.000
 mPSI V 6/22 (27.3) 5/13 (38.5) 0.708
 mPSI IV + V 15/133 (11.3) 6/35 (17.14) 0.390
Mean length of stay (d)
 All patients 16.16 16.64 0.860
 mPSI I 7.91 8.80 0.794
 mPSI II 9.00 12.75 0.607
 mPSI III 13.65 13.89 0.938
 mPSI IV 17.30 14.68 0.324
 mPSI V 27.23 26.08 0.909
 mPSI IV + V 18.94 18.91 0.995
MV use within 24 hr
 All patients 14/227 (6.2) 6/53 (11.3) 0.232
 mPSI IV 6/111 (5.4) 1/22 (4.5) 1.000
 mPSI V 6/22 (27.3) 5/13 (38.5) 0.708
 mPSI IV + V 12/133 (9.0) 6/35 (17.1) 0.216
MV use after 24 hr
 All patients 14/227 (6.2) 6/53 (11.3) 0.232
 mPSI IV 11/111 (9.9) 3/22 (13.6) 0.702
 mPSI V 2/22 (9.1) 2/13 (15.4) 0.618
 mPSI IV + V 13/133 (9.8) 5/35 (14.3) 0.538
aData presented as the number of positive cases/total number of cases in the group (%) or n. β-lactam = β-lactam-based therapy group; 
FQ = fluoroquinolones therapy group; mPSI = modified pneumonia severity index; MV = mechanical ventilation.
receiving β-lactam-based therapy than for those receiving 
FQ therapy (0% vs. 23%, respectively; p =  0.044). The 30-
day survival curve is shown in the Figure. The p values for 
14-day and 30-day survival between the groups were 0.019 
and 0.197, respectively.
Discussion
There is evidence showing that empiric FQ use in pul-
monary TB patients who initially present with a clinical 
picture of CAP is associated with delayed diagnosis and 
prolonged infectivity, greater morbidity and mortality 
and a prolonged period of spread of M. tuberculosis in the 
community.7,8 Although our study cohort contains cul-
ture-positive TB patients rather than CAP patients, this 
report shows the importance of judicious use of FQs as 
empiric antibiotics for CAP in a TB-endemic area. The 
current Taiwanese guidelines on antimicrobial therapy 
for pneumonia in adults published by the Infectious 
Diseases Society of Taiwan recommend that newer FQs 
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may be the drug-of-choice in the treatment of CAP, but 
emphasize that “when newer FQs are used, pulmonary TB 
should be considered and aggressive microbiological eval-
uation for M. tuberculosis should be performed”.17 This has 
affected the choice of antibiotics, as our results show that 
radiographic evidence of a prior TB infection increases 
the probability that a β-lactam-based regimen will be se-
lected for the treatment of CAP, since reactivation of TB is 
the major source of TB infection in non-HIV-infected 
adult patients.18,19 A history of prior TB infection is not 
an independent factor that influences the physician’s pre-
scription. Because some patients cannot provide enough 
(or correct) information, doctors still depend on radio-
graphic findings to choose empiric antibiotics.
In this study, the proportion of patients with mPSI cat-
egory V was significantly higher in the FQ therapy group 
than in the β-lactam-based therapy group. There are sev-
eral possible reasons for this. First, FQs, but not β-lactams, 
are active against high level penicillin-resistant strains of 
Streptococcus pneumoniae.20–22 Second, in Taiwan, FQs are 
available in intravenous form, but newer macrolides are 
available only in oral form for the treatment of atypical 
pathogens. Third, in some studies focusing on patients 
with Legionella pneumonia, the time-to-improvement of 
clinical symptoms, signs and laboratory examinations was 
shorter in those patients who received FQ therapy than 
patients who received macrolide therapy.23,24 Fourth, the 
disease course and clinical picture of severe pneumonia 
tends to be more fulminate, which is more common in 
acute bacterial pneumonia than in TB infection. 
Of the mPSI category V patients, there was only one 
clinical characteristic that showed a significant difference 
between the two treatment groups (increased hyponatremia 
in the β-lactam-based therapy group). However, the 14-day 
mortality was lower in the β-lactam-based therapy group. 
Despite a similar spectra of activity and favorable resist-
ance patterns against CAP pathogens, emerging evidence 
suggests the superiority of combination therapy (β-lactam 
with macrolides) over FQ monotherapy for certain popu-
lations; particularly patients with severe CAP or bactere-
mic pneumococcal CAP.25–34 The current Infectious Disease 
Society of America/American Thoracic Society guidelines 
on the management of CAP in adults recommends a 
β-lactam plus either azithromycin or an FQ in patients 
who are admitted to intensive care units.21 The superior-
ity of β-lactam-azithromycin combination therapy over 
FQ monotherapy for patients with severe CAP may be ex-
plained by many factors.33 Macrolides have immunomod-
ulatory properties that may contribute to the superiority 
of combination therapy.35–37 Several studies have demon-
strated that macrolides reduce the proinflammatory 
response to infectious stimuli, including many primary 
cytokines (such as interleukin-1, tumor necrosis factor-
alpha, interleukin-6 and interleukin-8). Modulation of 
the immune response may improve patient outcomes by 
diminishing the proinflammatory complications of sep-
sis such as secondary organ dysfunction. Macrolides also 
reduce the adherence of pneumococci to respiratory 
epithelial cells.38 In addition, the use of azithromycin and 
β-lactam, two agents with different mechanisms of action, 
may additively or synergistically enhance bacterial killing 
over that of single-agent therapy.39,40
There are some limitations in this study. Because of 
the retrospective nature of the investigation, the charac-
teristics of the patients in the two treatment groups were 
not fully randomized. No aggressive survey of etiologic di-
agnoses led to an identifiable pathogen in most patients. 
A probable etiological diagnosis implicated that the iden-
tified organism might be a colonization or a contami-
nant. A small sample size also restricted the power of the 
study.
In conclusion, radiographic evidence of a prior pulmo-
nary TB infection is the main factor that skews the choice 
of empiric antibiotics toward β-lactams for CAP. The pro-
portion of patients with mPSI category V was higher in 
Figure. The 30-day survival curve in patients with modified pneu-
monia severity index category V. β-lactam = β-lactam-based ther-
apy group; FQ = fluoroquinolones therapy group.
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the FQ therapy group. However, in patients with mPSI 
category V, the 14-day mortality rate was lower in the 
β-lactam group. In patients with severe CAP and with a 
risk of TB infection, β-lactam-based therapy is a safe and 
reliable choice of empirical treatment.
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